705 related articles for article (PubMed ID: 27879147)
21. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
23. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
24. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
26. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
27. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
28. A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease.
Brunger AF; Nienhuis HLA; Bijzet J; Roeloffzen WWH; Vellenga E; Hazenberg BPC
Amyloid; 2020 Jun; 27(2):119-127. PubMed ID: 32052655
[No Abstract] [Full Text] [Related]
29. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
30. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.
Seldin DC; Anderson JJ; Skinner M; Malek K; Wright DG; Quillen K; Finn K; Oran B; Sanchorawala V
Blood; 2006 Dec; 108(12):3945-7. PubMed ID: 16926284
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
Kaufman GP; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2015 Mar; 90(3):181-6. PubMed ID: 25388651
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
35. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
36. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
Landau H; Smith M; Landry C; Chou JF; Devlin SM; Hassoun H; Bello C; Giralt S; Comenzo RL
Leukemia; 2017 Jan; 31(1):136-142. PubMed ID: 27560108
[TBL] [Abstract][Full Text] [Related]
37. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
38. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.
Phull P; Sanchorawala V; Brauneis D; Sloan JM; Siddiqi OK; Quillen K; Sarosiek S
Bone Marrow Transplant; 2019 Aug; 54(8):1304-1309. PubMed ID: 30664726
[TBL] [Abstract][Full Text] [Related]
39. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]